Skip to main
ATOS
ATOS logo

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics Inc is positioned favorably due to its focus on developing innovative therapies for significant unmet medical needs in oncology and COVID-19, particularly through its promising drug pipeline, including Endoxifen for breast cancer and AT-H201 and AT-301 for COVID-19. The company’s current valuation is considered attractive, with a positive outlook supported by a net present value (NPV) analysis indicating substantial potential for appreciation from the current share price. Furthermore, the anticipation of achieving key clinical milestones and data is expected to act as a strong catalyst for stock performance, enhancing the overall investment appeal.

Bears say

Atossa Therapeutics Inc. reported a net loss of $8.4 million, equating to an earnings per share (EPS) of $(0.07), which was below both management and consensus estimates of $(0.06). The company faces significant risks, including liquidity challenges, potential failures of its drug candidates in clinical trials, and the ability to secure regulatory approvals and reimbursement, which could jeopardize commercialization efforts. Additionally, external factors such as competition and shifting investor sentiment toward biotech stocks may further exacerbate the negative outlook on the company's stock.

Atossa Genetics (ATOS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.